ecancer

Choosing Wisely in RT oncology

Management of HER2 positive metastatic breast cancer treatment algorithm

Spindle cell lesions of the breast

The role of lymph nodes in stage 3 lung cancer

Updates on HER2-low breast cancer

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC

AOH1996 treatment targeting PCNA shows promise for reoccurring solid tumours

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of MIBC patients

Stereotactic body radiotherapy compared with surgery for localised prostate cancer

New era of early cancer detection blood tests on the horizon

Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma

Olaparib continues to show positive results in advanced ovarian cancer - 7 year data

Metastatic breast cancer endpoints for survival: rwPFS and TTNT

Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-line recurrent/met...

Treatment algorithm in systemic management of advanced prostate cancer

Low-dose nivolumab leads to improved overall survival for head and neck cancer patients

R-CODOX-M/R-IVAC versus dose-adjusted-EPOCH-R in patients with newly diagnosed high-risk lymphoma

Ponatinib and blinatumomab for patients with Philadelphia chromosome-positive ALL

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma

LUMINA results: Women with low levels of the Ki67 biomarker can avoid outcomes related to RT

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic BC without prior chemotherapy pts

ASCO 2022: Breast cancer highlights

Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes...

Pembrolizumab demonstrates improvement in distant metastasis-free survival in patients with melanoma

Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to av...

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expression

Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer

NETs: Capecitabine plus temozolomide gives longer PFS than temozolomide alone

Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient LARC

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients

Neoadjuvant ipilimumab and nivolumab immunotherapy for resectable stage III melanoma

N-803-BCG combination shows promising results in BCG-unresponsive NMIBC

Adagrasib shows CNS penetration and encouraging intracranial activity for KRASG12C-mutated NSCLC

FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-type mCC

HIMALAYA: Study of tremelimumab and durvalumab as first-line therapy in patients with uHCC

Early treatment discontinuation and early oxaliplatin discontinuation for stage III colorectal c...

Durvalumab plus chemotherapy significantly improved OS in advanced biliary tract cancer

An AI-derived digital pathology-based biomarker to predict the benefit of ADT in PC with validat...

Prostate cancer patients receiving androgen-deprivation therapies shown to be at lower risk from...

Trastuzumab deruxtecan shows benefit across HER2+ metastatic breast cancer subgroups

The latest in Philadelphia chromosome-positive ALL (Ph+ ALL)

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity

ESMO 2021: Updates in hormone-sensitive prostate cancer

Advances in prostate cancer in the last 10 years and a glimpse to the future

Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical cancer

Neoadjuvant chemotherapy with CapeOx alone vs standard chemoradiotherapy (CRT) with Capecitabine...

Overall survival with abiraterone acetate plus prednisone in PEACE-1

Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLC

Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+ metastatic breast cancer

Giredestrant plus palbociclib vs anastrozole plus palbociclib for post-menopausal, HER2-negative...